Compare Bristol-Myers Squibb Co (BMY) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Bank of New York Mellon Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $129.94B), while Bank of New York Mellon Corp trades at $162.77 (market cap $108.78B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | BNY | |
|---|---|---|
Market Cap | $129.94B | $108.78B |
Sector | Health | Financials |
52-Week High | $65.89 | $162.35 |
52-Week Low | $42.60 | $101.00 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
BNY stock trades at $162.92, up 2.18% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.46 beating estimates and consistent revenue growth from $19.76B in 2025 to $21.0B projected for 2026. Analyst sentiment remains positive with 10 buy ratings and a $170.36 consensus price target, supported by recent digital transfer agency expansion and blockchain infrastructure collaborations.
Outlook remains favorable with earnings momentum and digital innovation driving growth, though elevated RSI levels suggest near-term consolidation risk. The stock offers 4.6% upside to consensus target with strong institutional support, balanced by competitive pressures in custody banking and interest rate sensitivity as key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
